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Incompletetransversemyelitis(ITM)ofunknownoriginisassociatedwithhighratesofmorbidityandmortality.Thisprospective,
open-label study was undertaken to determine whether antituberculous treatment (ATT) might help patients with ITM whose
condition continues to deteriorate despite receiving IV methylprednisolone treatment. The study consisted of 67 patients with
steroid-refractory ITM in whom Mycobacterium tuberculosis (MTB) was suspected clinically and in whom other known causes of
myelopathywere excluded. The study occurred from January 2003 to June2010.Patients underwent trial chemotherapy with ATT.
Eﬃcacy was assessed by the American Spinal Injury Association (ASIA) scoring system, the Barthel Index (BI) and the Hauser
Ambulation Index (AI) at baseline, 12 months, and 24 months, using magnetic resonance imaging (MRI). Of the 67 patients
enrolled, 51 were assessed and 16 withdrew. At 24 months, 49 patients experienced beneﬁts as indicated by signiﬁcantly increased
ASIA and BI scores. The Hauser AI index also improved with markedly decreased abnormal signals in spinal cord MRI over time.
Theresultsfromthisprospective study providebeneﬁcial clinicalandMRIdataontheeﬃcacyofATTinITM patientsandsuggests
mycobacteria may be an important and neglected cause of myelitis.
1.Introduction
Transverse myelitis is a focal inﬂammatory disorder of the
spinal cord, resulting in motor, sensory, and autonomic
dysfunction. It is a poorly deﬁned condition and displays
heterogeneousetiopathogenesis[1,2].Incompletetransverse
myelitis(ITM)isararesyndromeeasilyrecognizedinclinical
practice,withsymptomsandsignsproducingbilateralpartial
impairment of motor, sensory, and autonomic functions,
usually with an acute or subacute onset. Inﬂammation is
not only the commonest basis of ITM but is also the
most diﬃcult to identify [3]. This clinical picture can be
shared by variety of etiologies including diﬀerent bacterial
or viral infections. Clinical presentations of infectious and
demyelinating diseases of the spinal cord are protean and
often nonspeciﬁc. Magnetic resonance imaging (MRI) is
sensitive but lacks speciﬁcity and most of the lesions feature
high signal intensity on T2-weighted images. There does
not seem to be any clinical, immunological, or radiological
strategies that reliably distinguish between demyelinating,
infectious, inﬂammatory, vascular, neoplastic, or paraneo-
plastic etiologies. Therefore, physicians must be aware of
the many potential treatable etiologies for ITM which might
mean there exists an eﬃcient approach for the patients.
ITM is a well-recognized but rare symptom of Mycobac-
terium tuberculosis infection. However, in developing coun-
tries, mycobacteria infection remains a signiﬁcant and
threatening problem. Most mycobacteria infections in
humans result in asymptomatic, latent infections [4, 5]. So
the index of suspicion for these infections must therefore be
raised to a level in ITM. Open-label use of antituberculous
treatment (ATT) was reported as beneﬁcial in neuromyelitis
optica (NMO) patients’ refractory to immunotherapy [6].
Given the lackofproveneﬃcacioustreatments, thisprospec-
tive, uncontrolled trial was designed to test ATT eﬃcacy for
treating ITM. We assessed patient’s disability using a panel of
clinicalscalesatbaselineandafter1or2yearsofATT.Disease
progression was followed by sequential MRI studies.2 Clinical and Developmental Immunology
2.PatientsandMethods
This prospective, open-label study was conductedat the First
Aﬃliated Hospital of Sun Yat-sen University (Guangzhou,
China), from Jan 2003 to Jun 2010. The Neurology
Department in this hospital is a referral center focused on
CNS diseases and accepts patients from other hospitals in
southern china. Sixty-seven patients qualiﬁed for inclusion
in the study, according to the inclusion and exclusion criteria
(see below). There were 24 males and 43 females. The
male to female ratio was 6:11. The median patient age was
39.07 ± 18.33 years. A detailed neurological examination
was carried out, including evaluation of the motor, sensory,
visual, and sphincter systems. A Mantoux test, chest X-ray,
serum biochemistry, serum and cerebral spinal ﬂuid (CSF)
Borrelia, and human immunodeﬁciency virus (HIV) testing
were performed to exclude other diseases. The CSF cell
count, glucose, and protein levels were obtained from
lumbar punctures performed prior to the onset of ATT.
A direct smear for acid-fast bacillus and a M. tuberculosis
antibody test (PPD-lgG) were also conducted. The
presence of oligoclonal bands was recorded in 26 of
the 67 patients.
Upon admission, a spinal MRI was performed on all
patients. The number of levels aﬀected in the sagittal plane
in the T2 sequence was measured. A brain MRI was also
performed and if the MRI scan was not normal, the patient
was excluded.
2.1. Inclusion and Exclusion Criteria. This study was con-
ducted with patients in whom MTB was suspected clin-
ically but not proven based on conventional measures.
The inclusion criteria were (i) development of sensory,
motor, or autonomic dysfunction attributable to the spinal
cord, (ii) varying degrees of motor, sensory, and sphinc-
ter dysfunction (although not necessarily symmetric), but
without complete paraplegia, (iii) exclusion of extra-axial
compressive etiology by MRI, (iv) worsening symptoms
despite at least one 5-day course of IV methylprednisolone
(0.5–1g/day), and (v) negative CSF MTB cultures with
ac e l lc o u n t<50/mm3 and a total protein <1.5g/L. The
exclusion criteria were (i) sudden onset, (ii) history of
previous radiation to the spine within the last 10 years,
(iii) CNS manifestations of syphilis, Lyme disease, or HIV
infection, (iv) clear arterial distribution and clinical deﬁcit
consistent with thrombosis of the anterior spinal artery,
(v) history of clinically apparent optic neuritis, (vi) brain
MRI abnormalities suggestive of MS or clinically deﬁnitive
MS, and (vii) serologic or clinical evidence of connective
tissue disease, such as, sarcoidosis, Behcet’s disease, Sj¨ ogren’s
syndrome, systemic lupus erythematosus (SLE), or mixed
connective tissue disorder.
The university ethics committee approved the study. All
patients were informed of the potential short- and long-
term drug complications of ATT. Written informed consent
was obtained from patients who agreed to participate in the
study. Patients were instructed to contact the study neurolo-
gist in the event of neurological symptoms. Before the start
of ATT treatment, all patients received a baseline evaluation.
2.2. Study Drug Administration. Prior to ATT initiation,
all treatments with corticosteroids and other systemic
immunosuppressiontherapieswerediscontinued.Treatment
protocolsconsistedofthreeantituberculousdrugs(isoniazid,
rifampicin, and pyrazinamide for 9 months), followed by
a combination of isoniazid and rifampicin for 24 months.
The doses were isoniazid at 10mg/kg/day , rifampicin at
10mg/kg/day, and pyrazinamide at 25mg/kg/day. Treatment
was under extensive observation. All patients had weekly
liver function tests for the ﬁrst one month of therapy
and subsequently every 3 monthly (serum bilirubin, serum
transaminases (SGOT/SGPT), and alkaline phosphatase).
2.3.Assessments. Eligiblepatientsunderwent completephys-
ical and neurological examinations at entry, at 12 and 24
months, and as needed for assessment of acute relapses
or safety. The American Spinal Injury Association (ASIA)
standards [7] were adopted to assess subjects’ neurological
status. We used the ASIA Impairment Scale to evaluate
sensory and motor function of the degree of spinal injury.
Activities of daily living were assessed by the Barthel
Index (BI) (0–100 scale, with lower scores denoting less
independence in activities of daily living). Mobility was
scored by the Hauser Ambulation Index (AI) [8]( 0 – 9s c a l e
designed to assess mobility). All patients were followed for
at least 2 years after treatment. Quality of life changes were
measured by the ASIA, BI and AI indices at baseline and
at 24 months, along with evaluation by MRI. Each patient
was followed up and assessed by the same physician during
the study.
Multiple sclerosis was diagnosed according to McDonald
et al.’scriteria[9].Patients thatsubsequentlydevelopedoptic
neuritis with or without recurrent ATM, but had no clinical
manifestations or involvement of other parts of the CNS,
were classiﬁed as NMO according to Wingerchuk et al.’s
criteria [10].
2.4. Statistical Methods. Statistical analysis was performed
using Student’st-test on paired samples. SPSS 13.0 statistical
Analysis System software was used for statistical analysis.
3.Results
3.1. Demographic and Clinical Characteristics. The median
interval from onset to treatment with ATT was 7.5 months
(range, 1–57 months). The most common modality of
presentation was in the form of sensory-motor involvement
(59 patients, 88%). Motor impairment presented as asym-
metric weakness, paraparesis or even quadriparesis. Sensory
symptoms includednumbness orparesthesias. Eight patients
presented with just motor involvement (12%), whereas 26
patients (38.8%) had some form of urinary symptoms in
the form of absent bladder sensations, incontinence, or
increased urination frequency. Three patients had deﬁnitive
TBevidenceuponchestradiography(Mantouxtest ≥10mm
in 48 hours). Baseline demographic and clinical information
is reported in Table 1.
The CSF ﬁndings were as follows. Elevated opening
pressure (>200mm H2O) was present in eight patients, andClinical and Developmental Immunology 3
Table 1: Baseline demographic and clinical information at inclu-
sion.
Characteristic Treatment group
Number 67
Female/male 43/24
Age of study entry (years) mean ± SD 39.07 ± 18.33
Disease duration (months) 7.55 (range, 1–57)
Drop-out 16
Mantoux test
￿ 10mm. 48
Patients with CSF normal ﬁnding 12
Patients with abnormal MR change 43
pleocytosis was found in 29 patients (43.3%) with lympho-
cyte predominance. Protein level was increased (>0.45g/L)
in 42 patients, 5 patients (7.5%) had decreased glucose
concentration, and eight patients (11.9%) revealed a low
CSF chloride level. Overall, CSF was abnormal in 55 of 67
patients, with 12 (17.9%) completely normal.
Spinal MRI lesions were visible in 43 patients (64.2%).
Lesions were usually hypointense or isointense on T1-
weighted and hyperintense in T2-weighted sequences. In
14 cases, we observed obvious spinal cord swelling. DTPA-
enhanced MRI scans were performed for 19 patients, of
which 13 showed Gd-enhancement. Ring enhancement
and/or heterogeneous enhancement were common ﬁndings.
Two patients had associated syrinx. Brain MRI was per-
formed for all patients but did not reveal any infectious or
demyelinating lesions.
3.2. Followup. Sixteen (23.9%) of 67 patients discontinued
ATT within the ﬁrst year. Another three patients dropped
outduringthesecondyearmedicationbutwerestill followed
(Figure 1). Thus, complete 24-month data were available for
51 (76.1%) patients. The principle reasons for discontinua-
tion were either side-eﬀects or absence of perceived eﬃcacy.
Sixpatients withdrew early duetoadverse drugeﬀects.Three
patients dropped out because of physician or participant’s
perception of therapy ineﬀectiveness. Two patients dropped
out due to intramedullary spinal cord tumor considerations
that required visiting another hospital. Two patients stopped
treatmentbecauseofrelapse,andtwopatientsexhibitedpoor
compliance. One patient died following an undiagnosed
high fever and cerebral salt-wasting syndrome. The median
follow-up interval after initial ATT was 32.8 months (range,
24–92 months).
3.3. Treatment Eﬃcacy. Treatment was halted for patients
experiencing deteriorating clinical symptoms since 43/51
(84%)patientsexperiencedgoodresponseintheearlycourse
of ATT treatment. During the ﬁrst week, 18/51 (35%)
patients had considerable improvement in limb weakness.
Sphincter symptoms gradually ameliorated in 21/26 (81%)
patients. The clinical beneﬁt was sustained and continued to
improvein most cases. After oneyear, 49/51(96%)oftreated
patients had achieved marked improvement of neurological
signs, and ﬁve had experienced a full recovery without any
67 enrolled
16 withdrown
6 .a d v e r s ed r u ge ﬀects
3. lack of eﬃcacy
2 tumor consideration
2r e f u s e d
2. relapse
1. died
51 assessed at months 12
3 withdrown
1 tumor consideration
2 non-compliance
51 assessed at months 24
Figure 1: Trial proﬁle.
m o t o ro rs e n s o r ys e q u e l a e .S p i n a lc o r de v a l u a t i o ns h o w e d
improved ASIA scores, signiﬁcantly increased BI ratings,
and an improved Hauser AI. The beneﬁt was sustained
and continued to improve over the second year (Table 2).
However, the major improvement occurred during the ﬁrst
year of ATT treatment.
Neurological relapses were experienced by 9/51 (18%)
patients, although they improved upon active treatment.
During the ﬁrst year followup, 13 relapses occurred, pri-
marily in the initial three months (six relapses), with six
more occurring in the second year of ATT treatment. Four
patients who continued ATT treatment in relapses periods,
and did not receive other immunosuppressive treatment,
recovered, whereas ﬁve patientsthat receivedIVIG treatment
responded well. Two patients experienced relapse of visual
decline (at 6 months and 15 months, resp.) as limb weakness
greatly improved, although both patients repeatedly showed
a normal brain MRI. NMO diagnosis was established
according to Wingerchuk’s criteria. Similar to our previous
study [6], visual acuity gradually recovered without change
to our regimen. Eighteen relapses occurred in patients with
longitudinal extensive lesions, and one relapse occurred in a
patient involving less than two segments.
3.4. MRI Changes. Two-year observations based on MRI
imaging were completed for 33/51 (65%) patients who had
cord lesions. Abnormal symptoms and swollen spinal cords
progressivelydecreasedin32patientsaftertherapyinitiation,
and T2 signal abnormalities decreased markedly in size. This
happened in poorly deﬁned, extensively swollen cord lesions
(Figure 2), with spinal cord demyelination involving less
than two segments (Figures 3 and 4), and with longitudinal4 Clinical and Developmental Immunology
Table 2: The changes of spinal function scores on baseline and after 1 year and 2 years of ATT (51 patients).
Years ASIA sensory scores ASIA motor scores Barthel index Ambulation index
Baseline 184.02 ± 23.57 78.86 ± 14.51 74.42 ± 22.40 3.92 ± 2.06
Year 1 209.33 ± 21.42∗ 93.75 ± 8.03∗ 93.43 ± 10.61∗ 1.63 ± 1.72∗
Year 2 211.10 ± 19.96∗ 95.10 ± 8.34∗ 95.47 ± 6.25∗ 1.09 ± 1.36∗
Each value represents mean ± SEM. ∗Improvement in values is statisticallysigniﬁcant (P<. 05) from baseline (paired sample t-test).
(a) (b) (c) (d) (e)
(f) (g) (h) (i) (j)
Figure2:A25-year-oldwomanwasadmittedduetotheprogressive
weakness and parasthesia in both legs with voiding problem for
3 months. After 2-year ATT, her situation improved with good
recovery ofspinalfunction.TheMRIchangesareasfollows:(a)ﬁrst
MRI performed in August 2005, T1 weighted image showing cord
edema from T1 to bottom in the sagittal plane, with focal atrophy
and syrinx cavity, (b) T2-weighted image showing a contiguous
area of increased signal intensity, (c) cavity and band-like structure
on axial T1-weighted images, (d, e) after one year of treatment,
the swelling of cervical spinal cord greatly dissolved on sagittal
T1-weighted image; the syrinx cavity is obviously diminished, (f)
contiguous abnormal signal still left but diminished on the sagittal
T2-weighted image, (g) the lesion is still obvious on axial T2-
weighted images, (h, i) three years after treatment, the syrinx cavity
is not obvious, and (j) some parts of thoracic cord restore normal
signalonT2-weighted axialcord images.A smallcavity is visible on
T8, and increased signal intensity still exists below T9.
lesions involving more than three segments (Figures 5, 6,
and 7). Additionally, regions where well-deﬁned signals and
poorlydeﬁnedenhancementshadbeenseenonpretreatment
resolved with treatment. During the observational period,
however, a decreased intramedullary lesion burden was not
detected in two patients. One patient received an operation
at 19 months due to lesion expansion, and pathological
examination revealed an astrocytoma. The lesion remained
(a) (b) (c)
(d) (e) (f)
Figure 3: A 58-year-old female developed paraplegia and paresthe-
sias in August 2007; weakness slowly worsened. Pulse methylpred-
nisolone and IVIG were initiated with no resolution; she continued
to deteriorate. After 2-year ATT, her situation fully recovered. The
MRI changes are as follows:(a)sagittalT2-weighted imageshowing
a contiguous area of increased signal intensity spanning T2 to T3
level,(b)axialT2-weightedimagesrevealthestrongsignals,(c)axial
MRI images showing focal cord enhancement, (d) after 5 months
of ATT, the lesion decreased, (e) following 1-year ATT, sagittal T2-
weighted MRI ofthe thoraciccord reveals no abnormalsignals,and
(f) no lesion is visible on cross-sectional T2-weighted images.
in another patient with improved condition after 24-month
followup (Figure 8).
3.5. Adverse Events. Adverse events occurred in 16/67
patients (23.9%). Two patients had somnolence and weak-
ness due to hyponatremia during the ﬁrst months of ATT
treatment and quickly recovered on active therapy. No other
serious adverse eﬀects were seen but six patients withdrawn
early because of lethargy, nausea, and vague ill health.
Eight patients had mild gastrointestinal syndrome on active
therapy but were able to continue the trial and resolved
quickly. One death that occurred during the study was
considered unrelated to the trial.Clinical and Developmental Immunology 5
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 4: A 51-year-old female suﬀered from tetraparesis and
frequently paroxysmal tics of extremities for 3 months. ATT
treatment quickly improved her symptoms. After 2-year ATT, she
fully recovered without visible symptoms. The MRI changes are
as follows: (a) sagittal T1-weighted MRI showing focal thickening
of the cord at C2-C3 level, (b) sagittal T2-weighted MRI showing
a focal demyelinating lesion, (c) axial T2-weighted MRI showing
the lesion to involve the whole cord, (d) sagittal T2-weighted
MRI after 6 months of treatment, showing the swelling of the
cervical spinal cord and patchy abnormal signal have resolved, (e)
axial T2-weighted MRI showing an abnormal signal remains, (f)
sagittal T1-weighted MRI after 2 years of treatment is normal, (g)
sagittal T2-weighted MRI after 2 years of treatment revealing no
abnormalsignals,and (h) axial T2-weighted cord MRI after 2 years
of treatment.
4.Discussion
We report our experience with a select group of myelopathy
patients treated with ATT. This is the ﬁrst clinical study
to evaluate the therapeutic eﬀects of ATT on steroid-
refractory ITM. Sustained increases in ASIA scores and BI,
with decreased AI scores, show that treatment is eﬀective
in most cases. This study used only pure antituberculosis
chemotherapy, without adopting steroid and other immune
suppressing drugs. The encouraging results are not only
associated with signiﬁcantly improving the neurological
status of these patients, but also with beneﬁcial changes to
spinal lesions as determined by MRI. This study suggests
ATT has beneﬁcial eﬀects in some ITM patients, and that
M. tuberculosis infection may be an important cause of this
disease.
Tuberculosis is still a major health problem in many
parts of the world, especially Asia and Africa. However,
tuberculous intramedullary involvement is considered to
be very rare compared with tuberculous spondylitis or
arachnoiditis [11]. Since its ﬁrst description by Abercrombie
in 1829 [12], there have only been some isolated cases
reported. Atrueepidemiologicaland clinicalproﬁlehasbeen
elusive. This study shows mycobacterial infections might be
(a) (b) (c)
(d) (e) (f)
Figure 5: A 40-year-old woman had tetraparesis, C3 sensory
level, and urinary incontinence for ﬁve months. Pulse methylpred-
nisoloneand IVIG were initiated with no resolution.However, ATT
greatly improved her condition. The MRI changes are as follows:
(a) sagittal T1-weighted MRI showing thickening of the cervical
cord, (b) sagittal T2-weighted MRI showing a contiguous area of
increased signal intensity spanning C2 to C7, (c) axial T2-weighted
MRI showing the strong signal derived from the whole cord, (d)
sagittal T1-weighted MRI after 2 years of treatment is normal,
(e) sagittal T2-weighted MRI after 1 year of treatment, showing a
normal spinal cord, and (f) axial T2-weighted MRI, showing no
lesions.
more common than usually suspected in myelitis. However,
due to the absence of a sensitive laboratory test, many cases
may have been considered as “idiopathic” with a presumed
immune mediated pathophysiological mechanism, despite
extensive diagnostic workup.
The etiology of the MRI signal abnormalities remains
speculative. In the current series, the MRI signal changes in
ITM vary from a small single lesion to extended longitudinal
lesions over several spinal segments. In the literature, the
majority of ITM cases with a single lesion is diagnosed as
a clinically isolated syndrome (CIS), which later may be
converted to multiple sclerosis (MS) [13, 14]. However, not
all CIS patients develop MS. Another diagnostic problem
is posed by patients with long hyperintense MRI lesions,
involving three or more segments of the spinal cord,
or the so-called longitudinal extensive transverse myelitis
(LETM). Today, such patients are designated as part of the
NMO spectrum [15]. In this study, CIS and LETM lesions
were revealed gradually as the imaging resolution of the
abnormalities improved after ATT therapy was initiated.6 Clinical and Developmental Immunology
(a) (b) (c)
(d) (e) (f)
Figure 6: A 70-year-old female was admitted due to progressive
paraparesis, paresthesias, and urinary retention for 2 months. After
2-year of ATT, her situation improved. The MRI changes are
as follows: (a) sagittal T2-weighted image reveals a long, high
intensity signal from C1 to T1 in the spinal cord before treatment
regimen,(b)T1Wcontrastimageshowingpatchyenhancementand
thickening of the cord, (c) the diﬀuse lesions on axial T2-weighted
images, (d) a year later the swelling of the cervical spinal cord
disappeared on sagittal T1-weighted images, (e) the hyperintensity
resolved following1year ofATT, and(f) no lesion is visible on axial
T2-weighted images.
The results of the present study suggest that lesion length
may not correlate with diﬀerent pathological ﬁndings. It is
possible that aspects of LETM and CISare based on the same
mycobacteria etiology. However, this hypothesis may serve
as a basis for further studies since this small series of patients
and study design was not designed to address this important
question.
In this study, 24 patients (38.2%) develop ITM without
signs of demyelination or other abnormalities of the spinal
cord as determined by MRI. Previous reports [16]s h o w
patients in this group usually have worsening symmetrical
clinical symptoms of transverse spinal cord syndrome, in
which spinal MRI may show atrophic changes later. There
is no evidence in the literature that any eﬀective treatment
exists. However, ATT shows an excellent treatment eﬀect for
17 patients of this trial. It may be that these puzzling results
are associated with mycobacteria infection. It is noteworthy
that patients in this category may present with clinical
symptoms similar to that of tropical spastic paraparesis
(TSP), which has been associated with human T-cell lym-
photropic virus type 1 (HTLV-1) [17]. TSP diagnosis may
require exclusion by laboratory tests for HTLV-1 antibodies.
Nevertheless, trial ATT treatments may be beneﬁcial in
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 7: A 30-year-old male suﬀered from left paraparesis and
paresthesias for 1 month. MRI of the cervical spinal cord revealed
a demyelinating lesion in T2-weighted images extending from C4
to C7. Pulse methylprednisolone and IVIG were initiated with no
resolution.TheMRIchangesareasfollows:(a)sagittalT2-weighted
image reveals a high intensity signal from C4 to C7 before ATT
regimen, (b) sagittal T1-weighted MRI showing light thickening
of the cord with subtle intraparenchymal hyperintensity, (c) the
left local lesions on axial FLAIR sequences, (d) the hyperintensity
resolved following 6 months of ATT, (e) no lesion is visible on axial
T2-weighted images, and (f)–(h) no lesion is visible on follow-up
MRI after 2 years of treatment.
tuberculosis endemic areas where diagnosis is not deﬁnite,
but where no treatment is available to treat TSP patients.
We found that subsequent neurological relapses during
ATT treatment usually occur in at least some patients,
potentially through a mechanism similar to paradoxical
deterioration in tuberculosis. Paradoxical deterioration dur-
ing ATT is usually deﬁned as the clinical or radiological
deterioration of pre-existing tuberculous lesions or the
development of new lesions in a patient who initially
improved [18]. In three reported cases of acute myelopathy
associated with pulmonary tuberculosisthat have undergone
postmortem examination [19], the myelopathy had been
progressive or relapsing, and demyelination of the white
and grey matter was found in the spinal cord of all three
patients. Relapses in tuberculous myelopathy can recur
several times during treatment [20]. Reid and Bone reported
that clinical improvement can be achieved after steroid
therapy [21]. However, disease progression despite adequate
ATT treatment is well documented [22]. Although relapses
occurred in some patients, there was a tendency for the
relapse rate to decrease as treatment continued. In this
trial, two LETM patients experienced optica neuritis, and
hence satisﬁed criteria for a diagnosis of NMO. However,
both patients successfully recovered without changing the
regimen.Clinical and Developmental Immunology 7
(a) (b) (c)
Figure 8: A 67-year-old femalesuﬀered from progressive parapare-
sis and paresthesias for 1 month. There is a small demyelinating
lesion at the level between T9 and T10. Steroid pulsed treatment
worsenedher condition.After ATT, her weaknessquicklyimproved.
She tried to stop ATT two times during the early stage of treatment
due to drug side-eﬀects, but failed because her condition grew
worse.Althoughshegotbetter, thelesionseemstohavenotchanged
after 18 month treatment. (a) Sagittal T2-weighted image reveals a
smallhigh intensity signalbetween T9 and T10 before our regimen;
(b) sagittal T2-weighted image after 6 months of ATT; (c) the
lesion still exists on sagittal T2-weighted images after 18 months
of treatment.
There are still few reports describing the features
of tuberculous myelopathy detected by MRI. The ﬁrst
documented description of using MRI to determine
intramedullary spinal tuberculosis was published by Rhoton
et al. in 1988 [23]. Lesions are usually hypointense on
T1W images and iso-to-hyperintense on T2W images with
cord expansion. Ramdurg et al. reported the largest series
of 15 spinal intramedullary tuberculosis with varied MR
changes [24]. This study shows excellent clinical outcomes
can be obtained with a combination of medical treatment
and surgical management, although patients presenting late
had a poorer outcome. In our study, there was a signiﬁcant
eﬀect of ATT treatment on T2-lesion volume over time.
It is impressive that abnormal signals and expanded spinal
cords progressively decreased with ATT and even completely
disappeared in some cases. All these changes may just reﬂect
that the infection subsided. Perhaps a more fundamental
problem is related to the interpretation of results from
ATT trials. Further studies should investigate whether this
syndrome is due to an immune reaction to TB or a primary
TB infection.
There are methodological limitations to the current
study. This is an uncontrolled study, the number of patients
in the trial was small, and relapses were less well deﬁned.
Overall, the trial provides some inspiring data and indicates
ATT may be an eﬃcient, cost-eﬀective approach to some
patients.Basedonthisstudy,adouble-blindcontrolledstudy
of ATT eﬃcacy will need to be performed, preferably over a
longer duration and with a larger sample size.
5.Conclusion
We have presented a prospective pilot study on steroid-
refractory ITM. This study has identiﬁed, for the ﬁrst
time, the long-term clinical eﬃcacy of ATT in some steroid-
refractory ITM patients. Our results suggest that ATT
treatment can not only stop disease activity and progression
but may also result in a signiﬁcant recovery of ﬁxed
neurological deﬁcits. On the other hand, the study also
suggests that tuberculosis infection might be an important
and still neglected cause of myelitis. Additional eﬀorts must
be made to conduct well-designed trials since no other
eﬀective treatments currently exist.
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